Skip to main
VANI

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical Inc. is positioned favorably due to the promising potential of its candidate NPM-139, which could enhance the safety and tolerability of existing therapies like semaglutide, likely reducing patient discontinuation rates and fostering better dosing compliance. Additionally, the encouraging data showing that NPM-139 has resulted in a sustained weight loss of approximately 20% over six months substantiates its efficacy and market relevance. The advancement of NPM-139 into clinical development is supported by these positive findings, indicative of a strong future for the company's product pipeline.

Bears say

Vivani Medical Inc faces significant risks that contribute to a negative outlook on the company's stock, particularly centered around its lead product, NPM-139. The potential failure of NPM-139 in clinical trials, as well as the inability to gain regulatory approval, poses substantial uncertainty regarding the company's future revenue potential. Additionally, concerns regarding market size, penetration rates, competition, and dilution risk further compound the challenges the company may encounter in achieving commercial success.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.